Masters of Longevity - The Pulse

PR Newswire01 Jun 2026
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation (PR Newswire)

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Biotech readers will find a company announcement about a novel experimental therapeutic program, offering scientific background, expert commentary, and plans for early clinical development.

Key takeaways
  • Biohaven has initiated first-in-human dosing of BHV-8100 with favorable once-daily pharmacokinetics reported.
  • Brain-penetrant PKM2 modulator that promotes energetic restoration by tetramerizing PKM2.
  • Preclinical and ex vivo studies showed metabolic rescue and neuroprotection.
Science Daily - Health & Medicine01 Jun 2026
The forgotten organ that could predict how long you live (Science Daily - Health & Medicine)

The forgotten organ that could predict how long you live

The adult thymus takes center stage in this feature exploring new studies, expert commentary, and what the organ might mean for future health research.

Key takeaways
  • Thymic health also predicted better immunotherapy outcomes in patients with cancer.
  • AI analysis of CT scans in tens of thousands linked healthier adult thymuses to longer survival.
  • Healthier thymuses were associated with substantially lower heart disease and cancer risk.
Fight Aging!01 Jun 2026
AIYet Another Proposed Definition for Allostatic Load (Fight Aging!)

Yet Another Proposed Definition for Allostatic Load

A look at a new proteomics-based definition of allostatic load and its reported predictive advantages over traditional biomarker panels.

Key takeaways
  • ProAL50 was constructed from 50 circulating proteins using UK Biobank plasma proteomics.
  • Validation in CARDIA showed stronger prediction of cancer, diabetes, heart disease, lung and kidney disease.
  • Protein signals primarily mapped to lipid metabolic and immune-inflammatory biological pathways.
Longevity Technology01 Jun 2026
AIRubedo reports promising early trial results for anti-aging skin cream (Longevity Technology)

Rubedo reports promising early trial results for anti-aging skin cream

Report on preliminary clinical data for a novel topical anti-aging cream showing safety and early efficacy signals in treatment of sun-damaged skin.

Key takeaways
  • Topical RLS-1496 1% cream reduced actinic keratosis lesions by 46% at four weeks.
  • Untreated control lesions decreased by 11% over the same four-week period.
  • Study reported favorable safety with no serious adverse events or discontinuations.